Pizzi M, et al. (2015) Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth. Oncotarget 6, 6544-52 25788269

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S13-p - CDC37 (human) ▲

Modsite: VWDHIEVsDDEDETH SwissProt Entrez-Gene Orthologous residues CDC37 (human): S13‑p, CDC37 (mouse): S13‑p, CDC37 (rat): S13‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lymphoma, B cell lymphoma, non-Hodgkin's lymphoma, follicular lymphoma Relevant cell lines - cell types - tissues:  OCI-ly1 (B lymphocyte), OCI-ly10 (B lymphocyte), OCI-ly3 (B lymphocyte) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes no change compared to control all normal B-cells increase Increased in all lymphoma cell lines, silmitasertib decrease in Raji, Oci Ly10, Oci Ly19 DLBCL cell lines Associated Diseases Diseases Alterations Comments B cell lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, non-Hodgkin's lymphoma increased

S209-p - CK2B (human) ▲

Modsite: QAAsNFksPVktIR_ SwissProt Entrez-Gene Orthologous residues CK2B (human): S209‑p, CK2B (mouse): S209‑p, CK2B (rat): S209‑p, CK2B (chicken): S209‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lymphoma, B cell lymphoma, non-Hodgkin's lymphoma, follicular lymphoma Relevant cell lines - cell types - tissues:  OCI-ly1 (B lymphocyte), OCI-ly10 (B lymphocyte), OCI-ly3 (B lymphocyte) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes no change compared to control all normal B-cells increase Increased in all lymphoma cell lines, Associated Diseases Diseases Alterations Comments B cell lymphoma, follicular lymphoma, lymphoplasmacytic lymphoma, non-Hodgkin's lymphoma increased

S529-p - NFkB-p65 (human) ▲

Modsite: GLPNGLLsGDEDFSs SwissProt Entrez-Gene Orthologous residues NFkB‑p65 (human): S529‑p, NFkB‑p65 (mouse): S527‑p, NFkB‑p65 (rat): S528‑p Characterization Methods used to characterize site in vivo:  phospho-antibody, western blotting Disease tissue studied:  lymphoma, B cell lymphoma, non-Hodgkin's lymphoma, follicular lymphoma Relevant cell lines - cell types - tissues:  OCI-ly1 (B lymphocyte), OCI-ly10 (B lymphocyte), OCI-ly3 (B lymphocyte) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes silmitasertib decrease in Raji, Oci Ly10, Oci Ly19 DLBCL cell lines